Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difamilast ointment in pediatric atopic dermatitis
NCT03911401Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of difamilast in atopic dermatitis (AD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Responder Rate of Investigator's Global Assessment (IGA) of Disease Severity at Week 4. Started May 2019; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03911401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911401.